Per direction by fda in an email dated june 26, 2019, an emdr is being filed to submit new information obtained prior to a letter received on may 15, 2019, regarding the revocation of the asr for exemption e2013025.It was agreed upon with the fda that the date of awareness would be the date of the email received, which is june 26, 2019.(b)(6), july 8, 2019.The sample was not returned.The finished product met all specifications prior to being released for general distribution.The instructions for use which accompanies all devices currently addresses potential risks associated with surgically implanted materials.The instructions for use states in the adverse events: ¿potential adverse reactions are those typically associated with surgically implantable materials, including hematoma, seroma, mucosal or visceral erosion, infection, inflammation, sensitization, dyspareunia, scarification and contraction, fistula formation, extrusion and recurrence of vaginal wall prolapse.Perforations or lacerations of vessels, nerves, bladder, bowel, rectum, or any viscera may occur during needle passage." (b)(4).
|
The patient's attorney alleged a deficiency against the device.Per additional information received, the patient has experienced erosion, urinary problems, bowel problems and vaginal scarring.Reason for report: revocation of asr, report id number: (b)(4), corresponding exemption number: e2013025.
|